{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:33:26Z","timestamp":1787020406301,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The introduction of the novel therapy, Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) has been effective in improving weight gain in both clinical trials and real-world studies. However, the magnitude of this effect appears to be heterogeneous across patient subgroups. This study aims to identify potential determinants of heterogeneity in weight gain following 6-month ETI therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter, prospective cohort study enrolling 92 adults with CF at two major CF centers in Italy with follow-up visit at one month and six months from ETI initiation. The treatment\u2019s effect on weight changes was evaluated using mixed effect regression models that included subject-specific random intercepts and fixed effects for potential predictors of treatment response, time and a predictor-by-time interaction term.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean weight gain at six months from the start of treatment was 4.6\u00a0kg (95% CI: 2.3\u20136.9) for the 10 patients with underweight, 3.2\u00a0kg (95% CI: 2.3-4.0) for the 72 patients with normal weight, and 0.7\u00a0kg (95% CI: -1.6-3.0) for the 10 patients with overweight. After six months of ETI treatment, 8 (80%) of the patients with underweight transitioned to the normal weight category, while 11 (15.3%) of the normal-weight patients became overweight. The major determinants of heterogeneity in weight gain were the baseline BMI and the presence of at least one CFTR residual function mutation, explaining 13% and 8% of the variability, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results indicate that ETI is highly effective in improving weight gain in underweight subjects with CF. However, our data also suggests the need for close monitoring of excess weight gain to prevent potential cardiometabolic complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-023-02451-0","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T04:02:15Z","timestamp":1686974535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Heterogeneity of weight gain after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis"],"prefix":"10.1186","volume":"24","author":[{"given":"Andrea","family":"Gramegna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Majo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Alicandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cristiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Amati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Contarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Giovanni","family":"Fiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,17]]},"reference":[{"issue":"1","key":"2451_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65\u2013124. https:\/\/doi.org\/10.1016\/S2213-2600(19)30337-6","journal-title":"Lancet Respir Med"},{"key":"2451_CR2","doi-asserted-by":"publisher","unstructured":"Nagy R, Gede N, Ocskay K, Dobai BM, Abada A, Vereczkei Z, P\u00e1zm\u00e1ny P, Kat\u00f3 D, Hegyi P, P\u00e1rniczky A. Association of Body Mass Index With Clinical Outcomes in Patients With Cystic Fibrosis: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022 Mar 1;5(3):e220740. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0740. PMID: 35254432; PMCID: PMC8902650.","DOI":"10.1001\/jamanetworkopen.2022.0740"},{"issue":"1","key":"2451_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jcf.2019.10.004","volume":"19","author":"T Harindhanavudhi","year":"2020","unstructured":"Harindhanavudhi T, Wang Q, Dunitz J, Moran A, Moheet A. Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: a single-center analysis. J Cyst Fibros. 2020;19(1):139\u201345. https:\/\/doi.org\/10.1016\/j.jcf.2019.10.004","journal-title":"J Cyst Fibros"},{"key":"2451_CR4","doi-asserted-by":"crossref","unstructured":"Gramegna A, Aliberti S, Contarini M, Savi D, Sotgiu G, Majo F, Saderi L, Lucidi V, Amati F, Pappalettera M, Palange P, Blasi F. Overweight and obesity in adults with cystic fibrosis: an italian multicenter cohort study. J Cyst Fibros 2022 Jan;21(1):111\u20134. doi: 10.1016\/j.jcf.2021.05.002. Epub 2021 May 27. PMID: 34053868.","DOI":"10.1016\/j.jcf.2021.05.002"},{"key":"2451_CR5","doi-asserted-by":"publisher","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R, VX17-445-102 Study Group. ;. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019 Nov 7;381(19):1809\u20131819. https:\/\/doi.org\/10.1056\/NEJMoa1908639. Epub 2019 Oct 31. PMID: 31697873; PMCID: PMC7282384.","DOI":"10.1056\/NEJMoa1908639"},{"key":"2451_CR6","doi-asserted-by":"crossref","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS, VX17-445-103 Trial Group. ;. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1940\u20131948. doi: 10.1016\/S0140-6736(19)32597-8. Epub 2019 Oct 31. Erratum in: Lancet. 2020 May 30;395(10238):1694. PMID: 31679946; PMCID: PMC7571408.","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2451_CR7","doi-asserted-by":"crossref","unstructured":"Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor tezacaftorivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros. 2022 Mar;21(2):265\u201371. Epub 2021 Dec 1. PMID: 34862121.","DOI":"10.1016\/j.jcf.2021.11.012"},{"key":"2451_CR8","doi-asserted-by":"publisher","unstructured":"Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C, French Cystic Fibrosis Reference Network Study Group. ;. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med. 2021 Jul 1;204(1):64\u201373. https:\/\/doi.org\/10.1164\/rccm.202011-4153OC. PMID: 33600738.","DOI":"10.1164\/rccm.202011-4153OC"},{"key":"2451_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jpeds.2016.09.064","volume":"181S","author":"PM Farrell","year":"2017","unstructured":"Farrell PM, White TB, Ren CL, et al. Diagnosis of cystic fibrosis: Consensus Guidelines from the cystic Fibrosis Foundation [published correction appears in J Pediatr. 2017 May;184:243]. J Pediatr. 2017;181S:4\u2013S. 15.e1.","journal-title":"J Pediatr"},{"key":"2451_CR10","doi-asserted-by":"publisher","unstructured":"Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC. Tezacaftor-Ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med. 2017 Nov;23(21):2024\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1709847. Epub 2017 Nov 3. PMID: 29099333; PMCID: PMC6472479.","DOI":"10.1056\/NEJMoa1709847"},{"key":"2451_CR11","unstructured":"https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/topic-details\/GHO\/body-mass-index"},{"key":"2451_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.2041-210x.2012.00261.x","volume":"4","author":"S Nakagawa","year":"2013","unstructured":"Nakagawa S, Schielzeth H. A general and simple method for obtaining R2 from generalized Linear mixed-effects models. Methods Ecol Evol. 2013;4:133\u201342.","journal-title":"Methods Ecol Evol"},{"key":"2451_CR13","doi-asserted-by":"publisher","unstructured":"Stallings VA, Sainath N, Oberle M, Bertolaso C, Schall JI. Energy Balance and Mechanisms of Weight Gain with Ivacaftor treatment of cystic Fibrosis gating mutations. J Pediatr. 2018 Oct;201:229\u2013237e4. https:\/\/doi.org\/10.1016\/j.jpeds.2018.05.018. Epub 2018 Jul 18. PMID: 30029855.","DOI":"10.1016\/j.jpeds.2018.05.018"},{"key":"2451_CR14","doi-asserted-by":"publisher","unstructured":"Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM, PROMISE Study group. ;. Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med. 2022 Mar 1;205(5):529\u2013539. https:\/\/doi.org\/10.1164\/rccm.202108-1986OC. PMID: 34784492; PMCID: PMC8906485.","DOI":"10.1164\/rccm.202108-1986OC"},{"key":"2451_CR15","doi-asserted-by":"publisher","unstructured":"Caley L, Peckham D. Time to change course and tackle CF related obesity. J Cyst Fibros. 2022 Aug 12:S1569-1993(22)00640-3. https:\/\/doi.org\/10.1016\/j.jcf.2022.08.004. Epub ahead of print. PMID: 35970693.","DOI":"10.1016\/j.jcf.2022.08.004"},{"key":"2451_CR16","doi-asserted-by":"publisher","unstructured":"Barry PJ, Mall MA, \u00c1lvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D. VX18-445-104 Study Group. Triple therapy for cystic fibrosis Phe508del-Gating and -residual function genotypes. N Engl J Med. 2021 Aug;26(9):815\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2100665. PMID: 34437784; PMCID: PMC8982185.","DOI":"10.1056\/NEJMoa2100665"},{"key":"2451_CR17","doi-asserted-by":"publisher","unstructured":"Alekh P, et al. Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity. J Cyst Fibros. 2020 Mar;19(Suppl 1):10\u2013S14. https:\/\/doi.org\/10.1016\/j.jcf.2019.11.001","DOI":"10.1016\/j.jcf.2019.11.001"},{"key":"2451_CR18","doi-asserted-by":"crossref","unstructured":"Gramegna A, De Petro C, Leonardi G, Contarini M, Amati F, Meazza R, Carugo S, Blasi F. Onset of systemic arterial hypertension after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis: A case series. J Cyst Fibros. 2022 Apr 18:S1569-1993(22)00099 \u2013 6. doi: 10.1016\/j.jcf.2022.04.010. Epub ahead of print. PMID: 35450770.","DOI":"10.1016\/j.jcf.2022.04.010"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02451-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02451-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02451-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T19:25:48Z","timestamp":1700249148000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02451-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,17]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2451"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02451-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2130790\/v1","asserted-by":"object"}]},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,17]]},"assertion":[{"value":"4 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The CRUI-CARE TA funding note has been removed","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest in relation to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by local Institutional Ethical Committee, followed by the approval of the other local ethical committees (CE Milano Area B, parere n. 594_2016bis). All participants provided written informed consent to take part in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"164"}}